Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Drug Profile

Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Alternative Names: Alendronate/dextran/guanidine; Osteodex

Latest Information Update: 12 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DexTech Medical
  • Class Antihypercalcaemics; Antineoplastics; Antithrombotics; Bisphosphonates; Calcium regulators; Drug conjugates; Glucans; Plasma expanders; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bone metastases

Most Recent Events

  • 29 Jun 2016 Discontinued - Phase-II for Bone metastases (In the elderly, Metastatic disease, In adults) in Denmark (IV) (NCT02825628)
  • 01 May 2016 DexTech Medical initiates a phase II trial for Bone metastases (In adults, In the elderly, Metastatic disease) in Sweden (IV) (NCT02825628)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top